WDWenwen Ding

Wenwen Ding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenwen Ding has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Fuqiang Xu

    State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Key Laboratory of Magnetic Resonance in Biological Systems, Wuhan Center for Magnetic Resonance, Innovation Academy for Precision Measurement Science and Technology, Chinese Academy of Sciences, Wuhan, China

    1 shared publication
  • Li Wang

    School of Medicine, Jingchu University of Technology, Jingmen 448000, China

    1 shared publication
  • Meng Yang

    Jingchu University of Technology Jingmen China

    1 shared publication
  • Qing Liu

    University of Chinese Academy of Sciences Beijing China

    1 shared publication
  • Yue Liu

    Department of Radiation Biology, Faculty of Preventive Medicine, the Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment The Fourth Military Medical University Xi'an China

    1 shared publication

Latest Publications

  • Open Access

    Carbogen Inhalation Therapy for Epileptic Seizures: Mechanisms, Evidence, and Future Directions

    by Li Wang, Yue Liu, Wenwen Ding, Meng Yang, Qing Liu, Fuqiang Xu

    Background: Drug‐resistant epilepsy (DRE) affects nearly one‐third of patients and remains a major unmet clinical need, despite advances in anti‐seizure medications (ASMs). Carbogen, a low‐concentration carbon dioxide (CO 2 ) and oxygen (O 2 ) gas mixture, has reemerged as a physiology‐based therapy owing to renewed insights into pH‐sensitive seizure mechanisms. Methods: This review summarizes preclinical and clinical evidence on carbogen inhalation for seizure control. Mechanistic data on pH‐dependent ion channels, GABAergic inhibition, and adenosine signaling were condensed, and clinical outcomes across seizure types and inhalation protocols were compared for safety and efficacy. Results: Carbogen induces short‐term respiratory acidosis, lowering brain extracellular pH to activate acid‐sensitive ion channels (e.g., ASIC1a and NaV1.2), enhance GABAergic inhibition, and boost adenosine signaling. These effects are rapid, reversible, and distinct from conventional ASMs. Preclinical studies show strong seizure suppression, especially under hyperventilation‐induced alkalosis. Clinically, brief low‐dose inhalation (5% CO 2 for ≤ 3 min) is effective and well tolerated in focal and absence seizures, whereas earlier high‐concentration protocols caused adverse effects. Efficacy varies by seizure type: benefits in nonconvulsive status epilepticus (NCSE) are limited, and the CARDIF trial found no advantage for pediatric febrile seizures. Ongoing work, such as the CRESCENT trial, is exploring carbogen as an adjunct therapy for pediatric convulsive status epilepticus (CSE). Conclusions: Evidence supports carbogen's therapeutic promise and highlights the need for precise patient selection, controlled delivery, and comprehensive safety testing. Future research should develop biomarker‐guided, closed‐loop systems and test synergy with established ASMs to advance carbogen as a mechanism‐based therapy within precision epilepsy care.